In turn, the MAO-B inhibitor safinamide showed benefits in terms of ‘emotional well-being’, significantly improving the PDQ-39 score after six months and two years of treatment, while also reducing the experience of depression [156]. This evidence concerns the gene MAOB and depressive disorder.